Biotech Insider Buying: Arrowhead Research Corp. (NASDAQ:ARWR), Vital Therapies(NASDAQ:VTL), Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), RXi Pharmaceuticals Corporation (NASDAQ:RXII), CorMedix(NYSEMKT:CRMD)

Arrowhead Research Corp (NASDAQ:ARWR) CEO Christopher Richard Anzalone acquired 16,000 shares of Arrowhead Research Corp stock on the open market in a transaction that occurred on Wednesday, October 15th. The stock was purchased at an average cost of $6.32 per share, for a total transaction of $101,120.00. Following the completion of the purchase, the chief executive officer now directly owns 260,173 shares of the company’s stock, valued at approximately $1,644,293.Arrowhead Research Corp. (NASDAQ:ARWR) in last trading activity moved up 3.50% to close at $6.80. Company weekly performance is 15.65% while its quarterly performance stands at -41.68%. Arrowhead Research Corp. (NASDAQ:ARWR) is -75.39% away from its 52 week high.

Vital Therapies Inc. (NASDAQ:VTL) Director Lowell Sears purchased 1,429 shares of the company’s stock in a transaction that occurred on Wednesday, October 8th. The shares were purchased at an average cost of $17.50 per share, for a total transaction of $25,007.50. Following the completion of the transaction, the director now directly owns 58,572 shares of the company’s stock, valued at approximately $1,025,010.On last trading day Vital Therapies, Inc. (NASDAQ:VTL) moved up 3.76% to close at $16.85. Its volatility for the week is 10.34% while volatility for the month is 10.09%. Vital Therapies, Inc. (NASDAQ:VTL) monthly performance is -7.77%.

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director Jason Aryeh bought 11,000 shares of the company’s stock on the open market in a transaction dated Thursday, October 9th. The stock was purchased at an average price of $42.99 per share, with a total value of $472,890.00. Following the purchase, the director now directly owns 60,695 shares of the company’s stock, valued at approximately $2,609,278. On last trading day Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) moved up 0.82% to close at $50.65. Its volatility for the week is 4.99% while volatility for the month is 5.01%. LGND’s sales growth for past 5 years was 12.40% and its EPS growth for past 5 years was 15.70%. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) monthly performance is 5.35%.

RXi Pharmaceuticals Corp (NASDAQ:RXII) Executive CAUWENBERGH GEERT initiated a Buy transaction dated Monday 15 September 2014 for 5,000 shares. The shares were transacted at an average price of $2.1799, for a total value of $10,900. Following the completion of the transaction the executive now directly owns 36,000 shares.RXi Pharmaceuticals Corporation (NASDAQ:RXII) has 7.90% insider ownership while its institutional ownership stands at 10.80%. In last trading activity company’s stock closed at $2.13.

CorMedix Inc. (NYSEMKT:CRMD) Executive MILBY RANDY initiated a Buy transaction dated Monday 15 September 2014 for 3,654 shares. The shares were transacted at an average price of $2, for a total value of $6,248. Following the completion of the transaction the Executive now directly owns 18,901 shares. On Tuesday shares of CorMedix, Inc. (NYSEMKT:CRMD) closed at $1.66.

Leave a Reply

Your email address will not be published. Required fields are marked *

*